Critical Limb Ischemia ' Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Critical Limb Ischemia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Critical Limb Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia. Critical Limb Ischemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Critical Limb Ischemia.- A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Critical Limb Ischemia pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Critical Limb Ischemia ' Pipeline Review, H2 2012
Published on December 2012
Report Summary
Critical Limb Ischemia ' Pipeline Review, H2 2012
Summary
Global Markets Direct's, 'Critical Limb Ischemia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic development for Critical Limb Ischemia, complete with latest updates,
and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Critical Limb Ischemia. Critical Limb Ischemia - Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.
Scope
- A snapshot of the global therapeutic scenario for Critical Limb Ischemia.
- A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Critical Limb Ischemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 1/9

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Critical Limb Ischemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Critical Limb Ischemia 10
Critical Limb Ischemia Therapeutics under Development by Companies 12
Critical Limb Ischemia Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Critical Limb Ischemia Therapeutics ' Products under Development by Companies 21
Critical Limb Ischemia Therapeutics ' Products under Investigation by Universities/Institutes 23
Companies Involved in Critical Limb Ischemia Therapeutics Development 24
Aastrom Biosciences, Inc. 24
Athersys, Inc. 25
MultiGene Vascular Systems (MGVS) Ltd. 26
Arteriocyte Medical Systems, Inc. 27
TCA Cellular Therapy 28
ReNeuron Group plc 29
AnGes MG, Inc. 30
Pluristem Therapeutics Inc. 31
AcelleRX Therapeutics Inc. 32
Medistem, Inc. 33
Viromed Co., Ltd. 34
RNL BIO Co., Ltd. 35
Stempeutics Research Private Limited 36
Critical Limb Ischemia ' Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
MultiStem - Drug Profile 43
Product Description 43
Mechanism of Action 43
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 2/9

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
R&D Progress 43
ALO-212 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ixmyelocel-T - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PLX-PAD - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VM-202 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ReN-009 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MultiGeneAngio - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
beperminogene perplasmid - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
beperminogene perplasmid - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
JVS-100 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Autologous CD133+ Cells - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Mesendo - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Autologous Bone Marrow Cell Concentrate Transplantation - Drug Profile 67
Product Description 67
Mechanism of Action 67
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 3/9

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
R&D Progress 67
BM-MNC + G-CSF - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Umbilical Cord Blood Stem Cells - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Stempeucel-CLI - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Allogenic Mesenchymal Stem Cells - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Autologous Bone Marrow Stem Cell Transfer - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Autologous Bone Marrow Derived Mononuclear Cells - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Autologous Bone Marrow Mononuclear Cells - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Autologous Concentrated Bone Marrow Nucleated Cell Therapy - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
MSC_Apceth_001 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Autologous Bone Marrow Derived Stem Cells - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Endometrial Regenerative Cells - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Angiostem Derivatives - Drug Profile 82
Product Description 82
Mechanism of Action 82
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 4/9

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
R&D Progress 82
Angiostem Derivatives - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
autologous immunomagnetic selected CD133 cells - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
CTXCryo - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Autologous Adipose Tissue Derived Mesenchymal Stem Cell - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Autologous CD34-Positive Cells - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Refacell-CLI - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Critical Limb Ischemia Therapeutics ' Drug Profile Updates 89
Critical Limb Ischemia Therapeutics - Dormant Products 108
Critical Limb Ischemia ' Product Development Milestones 110
Featured News & Press Releases 110
Oct 29, 2012: Medistem To Present Data On Endometrial Regenerative Cell At Stem Cell Meeting On Mesa 110
Sep 11, 2012: ReNeuron Submits Clinical Trial Application For ReN001 In UK 110
Sep 11, 2012: ReNeuron Submits Clinical Trial Application For ReN009 In UK 111
Sep 04, 2012: Korean Researchers Publish Report On Adipose Stem Cell-Based Critical Limb Ischemia Treatment In Circulation
Journal 112
Jul 13, 2012: Medistem Launches Critical Limb Ischemia Clinical Trial 113
Jun 15, 2012: ReNeuron Presents Positive Preclinical Data Of ReN009 At 10th Annual Meeting Of International Society For Stem Cell
Research 113
May 15, 2012: Juventas Therapeutics Enrolls Patients In Phase IIa STOP-CLI Clinical Trial 114
May 09, 2012: Aastrom Enrolls First Patient In REVIVE Phase III Clinical Trial Of Ixmyelocel-T 114
Apr 05, 2012: Aastrom Announces Final Results From Phase IIb Clinical Trial Of Ixmyelocel-T In Treatment Of Critical Limb Ischemia
115
Feb 29, 2012: Aastrom Initiates Patient Enrollment In REVIVE Phase III Clinical Trial Of Ixmyelocel-T 116
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 5/9

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Contact Us 118
Disclaimer 118
List of Tables
Number of Products Under Development for Critical Limb Ischemia, H2 2012 10
Products under Development for Critical Limb Ischemia ' Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Development by Companies, H2 2012 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2012 23
Aastrom Biosciences, Inc., H2 2012 24
Athersys, Inc., H2 2012 25
MultiGene Vascular Systems (MGVS) Ltd., H2 2012 26
Arteriocyte Medical Systems, Inc., H2 2012 27
TCA Cellular Therapy, H2 2012 28
ReNeuron Group plc, H2 2012 29
AnGes MG, Inc., H2 2012 30
Pluristem Therapeutics Inc., H2 2012 31
AcelleRX Therapeutics Inc., H2 2012 32
Medistem, Inc., H2 2012 33
Viromed Co., Ltd., H2 2012 34
RNL BIO Co., Ltd., H2 2012 35
Stempeutics Research Private Limited, H2 2012 36
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 42
Critical Limb Ischemia Therapeutics ' Drug Profile Updates 89
Critical Limb Ischemia Therapeutics ' Dormant Products 108
Critical Limb Ischemia Therapeutics ' Dormant Products (Contd..1) 109
List of Figures
Number of Products under Development for Critical Limb Ischemia, H2 2012 10
Products under Development for Critical Limb Ischemia ' Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 15
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 6/9

7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 37
Assessment by Combination Products, H2 2012 38
Assessment by Route of Administration, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 40
Assessment by Molecule Type, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 42
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 7/9

8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Critical Limb Ischemia ' Pipeline Review, H2 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 000.00 Quantity: _____
Site License--USD 4 000.00 Quantity: _____
Corporate License--USD 6 000.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 8/9

9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Critical Limb Ischemia ' Pipeline Review, H2 2012 (From Slideshare) Page 9/9